Slingshot members are tracking this event:

Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXA-4 Study of Factor Xa Inhibitor Antidote AndexXa (andexanet alfa) in Patients with Acute Major Bleeding

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 30, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Anexxa-4, Factor Xa Inhibitor, Andexxa, Andexanet Alfa, Acute Major Bleeding, Warfarin